Education
About Us
Working with TipRanks
Follow Us
Eli Lilly And Company (DE:LLY)
NYSE:LLY
LLY Stock Chart & Stats
€869.50
€1.80(0.24%)
At close: 4:00 PM EST
€869.50
€1.80(0.24%)
Day’s Range― - ―
52-Week Range€535.80 - €971.10
Previous CloseN/A
Volume143.00
Average Volume (3M)2.09K
Market Cap
€815.57B
Enterprise Value€951.45B
Total Cash (Recent Filing)€9.91B
Total Debt (Recent Filing)€42.51B
Price to Earnings (P/E)43.8
Beta0.57
Next Earnings
Apr 30, 2026EPS Estimate
6.06Next Dividend Ex-DateN/A
Dividend Yield0.62%
Share Statistics
EPS (TTM)6.34
Shares Outstanding945,383,700
10 Day Avg. Volume3,280
30 Day Avg. Volume2,094
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)48.99
Price to Sales (P/S)15.44
P/FCF Ratio1.68K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1,057.64Price Target Upside21.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionAcquisition of Orna broadens the company's cell therapy capabilities and strengthens its oncology and immunology pipeline, potentially accelerating development of novel treatments.
Financial StrengthA strong balance sheet and reliable cash flow enable funding of higher-risk programs and sustained pipeline investment without materially impacting core business operations.
In Vivo CAR-T TechnologyIn vivo CAR-T approaches could lower manufacturing complexity and costs while enabling shelf-stable therapies, improving patient access and creating new commercial opportunities.
Bears Say
Compounding Disruptor ThreatEntry of a low-cost semaglutide pill distributed through telehealth-integrated compounding could scale personalized dispensing and disrupt both oral and injectable GLP-1 markets.
Guidance UncertaintyWide guidance ranges are likely because multiple swing factors in the incretin franchise make volume trends hard to predict, increasing the risk of earnings surprises and stock volatility.
Margin PressureHigher operating expenses and margin pressures may weigh on earnings per share relative to expectations, reducing near-term profitability upside.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly And Company’s price range in the past 12 months?
Eli Lilly And Company lowest stock price was €535.80 and its highest was €971.10 in the past 12 months.
What is Eli Lilly And Company’s market cap?
Eli Lilly And Company’s market cap is €815.57B.
When is Eli Lilly And Company’s upcoming earnings report date?
Eli Lilly And Company’s upcoming earnings report date is Apr 30, 2026 which is in 77 days.
How were Eli Lilly And Company’s earnings last quarter?
Eli Lilly And Company released its earnings results on Feb 04, 2026. The company reported €6.336 earnings per share for the quarter, beating the consensus estimate of €5.807 by €0.529.
Is Eli Lilly And Company overvalued?
According to Wall Street analysts Eli Lilly And Company’s price is currently Undervalued.
Does Eli Lilly And Company pay dividends?
Eli Lilly And Company pays a Quarterly dividend of €1.291 which represents an annual dividend yield of 0.62%. See more information on Eli Lilly And Company dividends here
What is Eli Lilly And Company’s EPS estimate?
Eli Lilly And Company’s EPS estimate is 6.06.
How many shares outstanding does Eli Lilly And Company have?
Eli Lilly And Company has 945,383,700 shares outstanding.
What happened to Eli Lilly And Company’s price movement after its last earnings report?
Eli Lilly And Company reported an EPS of €6.336 in its last earnings report, beating expectations of €5.807. Following the earnings report the stock price went up 6.692%.
Which hedge fund is a major shareholder of Eli Lilly And Company?
Currently, no hedge funds are holding shares in DE:LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Company Description
Eli Lilly And Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
LLY Company Deck
LLY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a strongly positive operational and financial picture: very large revenue and EPS growth, broad product and pipeline momentum (multiple Phase 3 successes and regulatory submissions), significant manufacturing scale-up, and a constructive 2026 guidance ($80–$83B revenue midpoint +25%). These positives are balanced by meaningful near-term headwinds including price erosion (US price decline ~7% in Q4 and price drag expected in the low-to-mid teens for 2026), higher R&D and commercial spend, some tolerability/discontinuation signals for specific programs, and temporary reimbursement/coverage reductions in Medicaid. On balance the company’s growth drivers, pipeline wins, commercial momentum, and capital allocation outweigh the challenges, but the business will need to manage price pressure and elevated investment levels as it scales.View all DE:LLY earnings summariesLLY Revenue Breakdown
90.47% Net product revenue
9.53% Collaboration and other revenue
LLY Stock 12 Month Forecast
Average Price Target
€1,057.64
▲(21.64% Upside)
Technical Analysis
Options Prices
Currently, No data available
---